Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Aline S.C. Fabricio, Silvia Michilin, Matelda Zancan, Valentina Agnolon, Lucia Peloso, Ruggero Dittadi, Antonio Scapinello, Claudio Ceccarelli & Massimo Gion. (2019) Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels. Scandinavian Journal of Clinical and Laboratory Investigation 79:4, pages 260-267.
Read now
Read now
Hidemi Kawajiri, Tsutomu Takashima, Shinichiro Kashiwagi, Satoru Noda, Naoyoshi Onoda & Kosei Hirakawa. (2015) Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Expert Review of Anticancer Therapy 15:1, pages 17-26.
Read now
Read now
Articles from other publishers (22)
Michael Galogre, Dmitry Rodin, Mikhail Pyatnitskiy, Melissa Mackelprang & Igor Koman. (2023) A review of HER2 overexpression and somatic mutations in cancers. Critical Reviews in Oncology/Hematology 186, pages 103997.
Crossref
Crossref
Wendong Bai, Hongyan Peng, Jiarui Zhang, Yongmei Zhao, Zhijun Li, Xuelian Feng, Jiang Zhang, Fei Liang, Li Wang, Nan Zhang, Yize Li, Huayu Zhu & Qiuhe Ji. (2022) LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer. npj Breast Cancer 8:1.
Crossref
Crossref
Jack D. Godfrey, Daniel Hejazi, Xiaofei Du, Cenfu Wei, Eshaan Rao & Christopher M. Gomez. (2022) HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA. International Journal of Molecular Sciences 23:17, pages 9549.
Crossref
Crossref
Tinslee Dilday & Elizabeth Yeh. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
11
34
.
Serenella M. Pupa, Francesca Ligorio, Valeria Cancila, Alma Franceschini, Claudio Tripodo, Claudio Vernieri & Lorenzo Castagnoli. (2021) HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers 13:19, pages 4778.
Crossref
Crossref
Babak Nami, Avrin Ghanaeian, Corbin Black & Zhixiang Wang. (2021) Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer. Life 11:9, pages 868.
Crossref
Crossref
Malene Bredahl Hansen, Maria Postol, Siri Tvingsholm, Inger Ødum Nielsen, Tiina Naumanen Dietrich, Pietri Puustinen, Kenji Maeda, Christoffel Dinant, Robert Strauss, David Egan, Marja Jäättelä & Tuula Kallunki. (2021) Identification of lysosome‐targeting drugs with anti‐inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers. Cellular Oncology 44:4, pages 805-820.
Crossref
Crossref
Hamid Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, Abdolvahab Moshtaghian & Zhixiang Wang. (2021) Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers 13:14, pages 3540.
Crossref
Crossref
Homa Seyedmirzaei, Mahsa Keshavarz-Fathi, Sepideh Razi, Masoumeh Gity & Nima Rezaei. (2021) Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). Journal of Oncology Pharmacy Practice 27:5, pages 1235-1244.
Crossref
Crossref
Fan Yang, Xiang Huang, Chunxiao Sun, Jianbin Li, Biyun Wang, Min Yan, Feng Jin, Haibo Wang, Jin Zhang, Peifen Fu, Tianyu Zeng, Jian Wang, Wei Li, Yongfei Li, Mengzhu Yang, Jun Li, Hao Wu, Ziyi Fu, Yongmei Yin & Zefei Jiang. (2020) Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population. BMC Cancer 20:1.
Crossref
Crossref
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, Nader Meskin, Semir Vranic & Ala-Eddin Al Moustafa. (2020) Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. Cancers 12:3, pages 636.
Crossref
Crossref
Doreen M. Floss & Jürgen Scheller. (2019) Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy. Cytokine & Growth Factor Reviews 47, pages 1-20.
Crossref
Crossref
Ditte Marie Brix, Siri Amanda Tvingsholm, Malene Bredahl Hansen, Knut Bundgaard Clemmensen, Tiina Ohman, Valentina Siino, Matteo Lambrughi, Klaus Hansen, Pietri Puustinen, Irina Gromova, Peter James, Elena Papaleo, Markku Varjosalo, José Moreira, Marja Jäättelä & Tuula Kallunki. (2019) Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion. Oncogene 38:17, pages 3170-3184.
Crossref
Crossref
Siri Amanda Tvingsholm, Ditte Marie Brix & Tuula Kallunki. (2018) Molecular and Transcriptional Signatures for ErbB2-Induced Invasion. Current Pharmacology Reports 5:1, pages 43-55.
Crossref
Crossref
Babak Nami, Hamid Maadi & Zhixiang Wang. (2018) Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers 10:10, pages 342.
Crossref
Crossref
Chi-Chih Kang, Toby M. Ward, Jessica Bockhorn, Courtney Schiffman, Haiyan Huang, Mark D. Pegram & Amy E. Herr. (2018) Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. npj Precision Oncology 2:1.
Crossref
Crossref
Sabrina Amar, Dmitriy Minond & Gregg B. Fields. (2017) Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases. PROTEOMICS 17:23-24, pages 1600389.
Crossref
Crossref
Yelena Y. Janjigian & Maria Ignez Braghiroli. (2017) Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. Surgical Oncology Clinics of North America 26:2, pages 313-324.
Crossref
Crossref
Reiki Nishimura, Uhi Toh, Maki Tanaka, Michiyo Saimura, Yasuhiro Okumura, Tsuyoshi Saito, Toshihiro Tanaka, Megumi Teraoka, Kazuo Shimada, Kazuhisa Katayama, Toshihiro Koga, Kaname Kurashita, Satoshi Hasegawa, Hidekazu Todoroki, Yuichiro Kai, Yasuyo Ohi, Satoshi Toyoshima, Nobuyuki Arima, Shoshu Mitsuyama & Kazuo Tamura. (2017) Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. Oncology 93:1, pages 51-61.
Crossref
Crossref
Marcia L. Moss & Dmitry Minond. (2017) Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators of Inflammation 2017, pages 1-21.
Crossref
Crossref
Zijia Sun, Yaqin Shi, Yan Shen, Lulu Cao, Wenwen Zhang & Xiaoxiang Guan. (2015)
Analysis of different
HER
‐2 mutations in breast cancer progression and drug resistance
. Journal of Cellular and Molecular Medicine 19:12, pages 2691-2701.
Crossref
Crossref
Giuseppe Viale. (2015) A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. The Breast 24, pages S23-S25.
Crossref
Crossref